Related Experiment Video
Updated: Feb 10, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
A validated UPLC-MS/MS method for the quantitation of an unstable peptide, monocyte locomotion inhibitory factor
Xuemei Liu1, Pei Hu1, Yongsheng Wang2
1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, PR China; Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, PR China.
Abstract:
Monocyte locomotion inhibitory factor (MLIF, Met-Gln-Cys-Asn-Ser), a pentapeptide with anti-inflammatory activity, was developed for neural protection in acute ischemic stroke. Determination of MLIF in human plasma samples is of great importance for pharmacokinetic evaluation in clinical studies. A reliable and sensitive method based on ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) was established for the measurement of MLIF in human plasma. Instability of peptide in matrix was the primary challenge in method development, which was properly resolved by addition of acidification reagents like sulfuric acid. Samples were prepared by protein precipitation and then analyzed using a gradient chromatographic separation over an ACQUITY UPLC HSS T3 column. The mobile phase consisted of acetonitrile containing 0.2% formic acid and water containing 0.2% formic acid and gradient elution was performed at a flow rate of 0.4 mL/min. Detection was carried out on a Xevo TQ-S tandem mass spectrometer and positive electrospray ionization was employed in the multiple reaction monitoring (MRM) mode. This method was fully validated over the concentration range of 0.5-40 ng/mL with a lower limit of quantification (LLOQ) of 0.5 ng/mL. The inter- and intra-batch precision was no more than 8.8% and the accuracy was between 88.7 and 104.2%. The mean extraction recovery was 43.3% and the detection was independent of matrix. Besides, the analyte proved to be stable under various handling processes and storage conditions after acidification. Finally, the method was applied to the first-in-human (FIH) study of MLIF in Chinese healthy subjects.
Insights
A new ultra-performance liquid chromatography-tandem mass spectrometry method accurately measures Monocyte Locomotion Inhibitory Factor (MLIF) in human plasma. This validated assay is crucial for pharmacokinetic studies of MLIF, a peptide used for neural protection in stroke.
Area of Science:
- Analytical Chemistry
- Pharmacokinetics
- Neuroscience
Background:
- Monocyte Locomotion Inhibitory Factor (MLIF) is a pentapeptide with anti-inflammatory properties, investigated for neural protection in acute ischemic stroke.
- Accurate quantification of MLIF in human plasma is essential for pharmacokinetic evaluation in clinical trials.
- Peptide instability in biological matrices presents a significant challenge for bioanalytical method development.
Purpose of the Study:
- To develop and validate a sensitive and reliable ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for measuring MLIF in human plasma.
- To address and overcome the challenge of MLIF instability in plasma samples.
- To apply the validated method in a first-in-human study.
Main Methods:
- Human plasma samples were prepared using protein precipitation followed by acidification with sulfuric acid to ensure MLIF stability.
- Chromatographic separation was performed on an ACQUITY UPLC HSS T3 column using a gradient elution with acetonitrile and formic acid in water.
- MLIF was detected using a Xevo TQ-S tandem mass spectrometer with positive electrospray ionization in multiple reaction monitoring (MRM) mode.
Main Results:
- The UPLC-MS/MS method was fully validated for MLIF quantification over a concentration range of 0.5-40 ng/mL, with a lower limit of quantification (LLOQ) of 0.5 ng/mL.
- The method demonstrated excellent precision (inter- and intra-batch ≤ 8.8%) and accuracy (88.7-104.2%), with a mean extraction recovery of 43.3% and no significant matrix effect.
- The developed method confirmed MLIF stability under various handling and storage conditions post-acidification.
Conclusions:
- A robust and sensitive UPLC-MS/MS method was successfully established for the accurate determination of MLIF in human plasma.
- The method's validation and stability assessments confirm its suitability for pharmacokinetic studies.
- The method was successfully applied to a first-in-human study of MLIF in healthy Chinese subjects, enabling crucial pharmacokinetic evaluations.
Related Concept Videos
Reliability and Validity
Measurement of Bioavailability: Pharmacokinetic Methods
Peptide Bonds
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
Transcription Factors
Data Validation
Key parameters for method validation include:

